NEW YORK – Cambridge, Massachusetts-based Cue Biopharma today announced that it is collaborating with Merck to evaluate its investigational biologic, CUE-101, in combination with Merck's checkpoint inhibitor pembrolizumab (Keytruda) as a first-line therapy for patients with HPV-positive, advanced head and neck cancer.